Traditional pharmacological treatments for spasticity part II: General and regional treatments

Muscle and Nerve

Volumn 20, Issue SUPPL. 6, 1997, Pages

  Gracies, Jean Michel ^a,d   Elovic, Elie ^b   McGuire, John ^c   Simpson, David ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b JFK JOHNSON REHABILITATION INSTITUTE   (United States)

^c REHABILITATION INSTITUTE OF CHICAGO   (United States)

^d Department of Neurology ^*  (United States)

Author keywords

Baclofen; Benzodiazepines; Botulinum toxin; Dantrolene; GABAergic drugs; Intrathecal delivery; Muscle overactivity; Spasticity; Tizanidine

Indexed keywords

EID: 0002738203     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (163)

1. Gracies J-M, Elovic E, McGuire J, Simpson D: Traditional pharmacological treatments for spasticity Part I: local treatments, Muscle Nerve 1997; 20 (suppl 6):S61-S91.
2. Lund S, Lundberg A, Vyklicky L: Inhibitory action from the flexor reflex afferents on transmission to Ia afferents. Acta Physiol Scand 1965; 64:345-355.
3. Davidoff RA: Antispasticity drugs: mechanisms of action. Ann Neurol 1985; 17:107-116.
4. Katz RT, Campagnolo DI: Pharmacologic care of the spastic patient, in Katz RT (ed): "Spasticity."State of the Art Reviews in Physical Medicine and Rehabilitation. Volume 8, Number 3. Philadelphia, Hanley & Belfus, 1994.
5. Whyte J, Robinson KM: Pharmacologic Management, in Glenn M, Whyte J (eds): The Practical Management of Spasticity in Children and Adults. Philadelphia, Lea & Febiger, 1990.
6. B sites in rat brain. Nature 1981; 290:149-152.
7. Van Hemet JCJ: A double-blind comparison of baclofen and placebo in patients with spasticity of cerebral origin, in Feldman RG, Young RR, Koella (eds): Spasticity: Disordered Motor Control. Chicago, Year Book Medical Publishers, 1980.
8. Pedersen E, Arlien-Soborg P, Grynderup V, Henriksen O. GABA derivative in spasticity. Acta Neurol Scand 1970; 46:257-266.
9. From A, Heltberg A: A double-blind trial with baclofen and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand 1975; 51:158-166.
10. Reisman Mann N, Gans BM: Hallucinations associated with acute baclofen withdrawal: report of two pediatric cases. Poster presented at the 47th Annual Assembly of the American Academy of Physical Medicine and Rehabilitation. Kansas City, MO, October 2, 1985.
11. Khorasani A, Peruzzi WT: Dantrolene treatment for abrupt intrathecal baclofen withdrawal. Anesth Analg 1995; 80:1054-1056.
12. Gerkin R, Curry SC, Vance MV, Sankowski PG, Meinhart RD: First order elimination kinetics following baclofen overdose. Ann Emerg Med 1986; 15(7):115-118.
13. Bergamini L, Roccio A, Bergamasco B: Un farmaco ad azione antispastica della muscolatura striata. Sperimentazione clinica di un derivato del Gaba. Minerva Med 1966; 57:2723-2729.
14. Birkmayer W, Danielczyk W, Weiler G: Zur Objektivierbarkeit des myotonolytischen Effektes eines Aminobuttersaurederivates (Ciba 34, 647. Ba). Wien Med Wschr 1967; 117(1):7-9.
15. Castadena C: Investigation to Ciba 34, 647-Ba en los sindromes espaticos neurologicos. Sem Med Mex 1967; 54 (1):13-16.
16. Morales LR: Efectos clinicos y terapeuticos del Ciba 34, 756-Ba en los sindromes espaticos. Mex Med 1967; 54(2):187-192.
17. Jerusalem F: Doppeltblindstudie über den anti spatiachen effekt von ß-(4-chlorophenyl)-γ-aminobuttersaure (Ciba) bei multiple Skleronse. A double-blind study on the antispastic action of ß-(4-chlorophenyl)-γ-amino butyric acid (CIBA) in multiple schlerosis. Nervenarzt 1968;39:515.
18. Jones RF, Burke D, Marosszeky JE, Gillies DJ: A new agent for the control of spasticity J Neurol Neurosurg Psychiatry 1970; 33:464-468.
19. Hudgson P, Weightman D: Baclofen in the treatment of spasticity. Br Med J 1971; 4:15-17.
20. Castaigne P, Held JP, Laplane D, Pierrot-Deseilligny E, Bussel B, Macquart-Moulin J: Étude de l'effet du Liorésal dans la spasticité. Revue Neurol (Paris) 1973; 128(4):245-250.
21. Ashby P, White D: "Presynaptic" inhibition in spasticity and the effect on ß-(4-chlorophenyl) GABA. J Neurol Sci 1973; 20:329-338.
22. Knutsson E, Lindblom U, Martensson A. Differences in effect in gamma and alpha spasticity induced by the GABA derivative baclofen (Lioresal). Brain 1973; 96:29-46.
23. Basmajan JV, Yucel V: Effects of a GABA-derivauve (BA-34647) on spasticity. Am J Phys Med 1974; 53(5):223-228.
24. Basmajan JV: Lioresal (baclofen) treatment of spasticity in multiple sclerosis. Am J Phys Med 1975; 54(4):175-177.
25. Duncan GW, Shahani BT, Young RR: An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. Neurology 1976; 441-446
26. Levine IM, Jossmann PB, DeAngelis V: Lioresal, a new muscle relaxant in the treatment of spasticity: a double-blind quantitative evaluation. Dis Nerv Sys 1977; 38:1011-1015.
27. McLellan DL: Co-contraction and stretch reflexes in spasticity during treatment with baclofen. J Neurol Neurosurg Psychiatry 1977; 40:30-38.
28. Feldman RG, Kelly-Hayes M, Conomy JP, Foley JM: Baclofen for spasticity in multiple sclerosis: double-blind crossover and three-year study. Neurology 1978; 28:1094-1098.
29. Sawa GM, Paty DW: The use of baclofen in treatment of spasticity in multiple sclerosis. Can J Neurol Sci 1979; 6(3):351-354.
30. Hinderer SR, Lehmann JF, Price R, White O, DeLateur BJ, Deitz J: Spasticity in spinal cord injured persons: quantitative effects of baclofen and placebo treatments. Am J Phys Med Rehabil 1990; 69(6):311-317.
31. Jones RF, Lance JW: Baclofen (Lioresal) in the long-term management of spasticity. Med J Aust 1976; 1:654-657.
32. Pedersen E, Arlien-Soborg P, Mai J: The mode of action of the GABA derivative baclofen in human spasticity. Acta Neurol Scand 1974; 50:665-680.
33. Pinto OD, Polker M, Debono G: Results of international clinical trials with Lioresal. Postgrad Med J 1972; 48 (Suppl 5):18-23.
34. Kirklan LR: Baclofen dosage: a suggestion (letter). Arch Phys Med Rehabil 1984; 65:214.
35. Smith CR, LaRocca NG, Giesser BS, Scheinberg L: High-dose oral baclofen: experience in patients with multiple sclerosis. Neurology 1991; 41: 1829-1831.
36. Olsen RW: GABA-benzodiazepine-barbiturate receptor interactions. J Neurochem 1987; 37:1-13.
37. Costa E, Guidotti A: Molecular mechanisms in the receptor action of the benzodiazepines. Ann Rev Toxicol 1979; 19:531-545.
38. Schwarz M, Turski L, Janiszewski W, Sontag K-H: Is the muscle relaxant effect of diazepam in spastic mutant rats mediated through GABA-independent benzodiazepine receptors? Neurosci Lett 1983; 36:175-180.
39. Pedersen E: Clinical assessment and pharmacologic therapy of spasticity. Arch Phys Med Rehabil 1974; 55:344-354.
40. Delwaide PJ: Étude expérimentale de l'hyperréflexi tendineuse en clinique neurologique. Thése Bruxelles, Arscia, 1971.
41. Matthew WB: Ratio of maxium H reflex to maximum M response of spasticity. J Neurol Neurosurg Psychiat 1966; 29:201-204.
42. Serfaty M, Masterton G: Fatal poisonings attributed to benzodiazepines in Britain during the 1980s. Br J Psych 1993; 163:386-393.
43. Tseng T, Wang S. Locus of action of centrally acting muscle relaxants diazepam and tybamate. J Pharmacol Exp Ther 1971; 178:350-360.
44. Kendall HP: The use of diazepam in hemiplegia. Ann Phys Med 1964; 7(6):225-228.
45. Cocchiarella A, Downey JA, Darling RC: Evaluation of the effect of diazepam on spasticity. Arch Phys Med Rehabil 1967; 49:393-396.
46. Stahl MM, Saldeen P, Vinge E: Reversal of fetal benzodiazepine intoxication using flumazenil. Br J Obstet Gynaecol 1993; 100:185-188.
47. Geller A: Common addictions. Clinical Symposia 1996; 48:23-24.
48. Corbett M, Frankel HL, Michaelis L: A double-blind cross-over trial of valium in the treatment of spasticity. Paraplegia 1972; 10:19-22.
49. Wilson LA, McKechnie AA: Oral diazepam in the treatment of spasticity in paraplegia: a double-blind trial and subsequent impressions. Scott Med J 1966; 11:46-51.
50. Verrier M, Ashby P, Macleod S: Diazepam effect on reflex activity in patients with complete spinal lesions and in those with other causes of spasticity. Arch Phys Med Rehabil 1977; 58:148-153.
51. Cook JB, Nathan PW: On the site of action of diazepam in spasticity in man. J Neurol Sci 1967; 5:33-37.
52. Engle HA: The effect of diazepam (Valium) in children with cerebral palsy: a double-blind study Dev Med Child Neurol 1966; 8:661-667.
53. Marsh HO: Diazepam in incapacitated cerebral-palsied children. JAMA 1965; 191(10):797-800.
54. Cartlidge NEF, Hudgson P, Weightman D. A comparison of baclofen and diazepam in the treatment of spasticity. J Neurol Sci 1974; 23:17-24.
55. Roussan M, Terrence C, Fromm G. Baclofen versus diazepam for the treatment of spasticity and long term follow-up of baclofen therapy. Pharmatherapeutica 1987; 4(5):278-284.
56. Lossius R, Dietrichson P, Lunde PKM: Effect of clorazepate in spasticity and rigidity: a quantitative study of reflexes and plasma concentrations. Acta Neurol Scand 1985; 71:190-194.
57. Scharf MB, Hirschowitz J, Woods M, et al: Lack of amnestic effects of clorazepate on geriatric recall. Clin Psychiatr 1985; 46(2):518-520.
58. Romney DM, Angus WR: A brief review of the effect of diazepam on memory. Psychopharm Bull 1984; 20(2):313-316.
59. Basmajan JV, Shankardass K, Russell D, et al: Ketazolam treatment for spasticity: double-blind study of a new drug. Arch Phys Med Rehabil 1984; 65:698-701.
60. Basmajan JV, Shandarkass K, Russell D. Ketazolam once daily for spasticity: double-blind cross-over study. Arch Phys Med Rehabil 1986; 67:556-557.
61. Cendrowski W, Sobczyk W: Clonazepam, baclofen, and placebo in the treatment of spasticity. Eur Neurol 1977; 16:257-262.
62. Milanov I: Mechanisms of tetrazepam action on spasticity. Acta Neurol Belgica 1992; 92 (1):5-15.
63. Maritz NG, Muller FO, Pompe van Meerdervoort HF: Piracetam in the management of spasticity in cerebral palsy. S Afr Med J 1978; 53:889-891.
64. Mondrup K, Pedersen E: The effect of the GABA-agonist, progabide, on stretch and flexor reflexes and on voluntary power in spastic patients. Acta Neurol Scand 1984; 69:191-199.
65. Mondrup K, Pedersen E: The clinical effect of the GABA-agonist, progabide, on spasticity. Acta Neurol Scand 1984; 69:200-206.
66. Rudick RA, Breton D, Krall RL: The GABA-agonist progabide for spasticity in multiple sclerosis. Arch Neurol 1987; 44:1033-1036.
67. Tardieu G, Shentoub S, Delarue R: À la récherche d'une technique de mesure de la spasticité. Revue Neurol 1954; 91(2):143-144.
68. Held JP, Pierrot-Deseilligny E: Rééducation Motrice des Affections Neurologiques. Paris, JB Baillère, 1969, pp 31-42.
69. Ward A, Chaffman MO, Sorkin EM: Dantrolene: a review of its pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 1986; 32:130-168.
70. Herman R, Mayer N, Mecomber SA: Clinical pharmaco-physiology of dantrolene sodium. Am J Physical Med 1972; 51:296-311.
71. Ellis KO, Carpenter JF: Mechanisms of control of skeletal muscle contraction by dantrolene sodium. Arch Phys Med Rehabil 1974; 55:362-369.
72. Pinder RM, Brogden RN, Speight TM, Avery GS: Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1977; 13:3-23.
73. Monster AW, Tamai Y, McHenry J: Dantrolene sodium: its effects on extrafusal muscle fibers. Arch Phys Med Rehabil 1974; 55:355-362.
74. Mai J, Pedersen E: Mode of action of dantrolene sodium in spasticity. Acta Neurol Scand 1979; 59: 309-316.
75. Flewellen EH, Nelson TE, Jones WP, Arens JF, Wagner DL: Dantrolene dose response in awake man: implications for management of malignant hyperthermia. Anesthesiology 1983; 59:275-280.
76. Katrak PH, Cole A, Poulos CJ, McCauley JCK: Objective assessment of spasticity, strength and function with early exhibition of dantrolene sodium after cerebrovascular accident: a randomized double-blind study. Arch Phys Med Rehabil 1992; 73:4-9.
77. Luisto M, Moller K, Nuutila A, et al: Dantrolene sodium in chronic spasticity of varying etiology. Acta Neurol Scand 1982; 65:355-362.
78. Monster AW: Spasticity and the effect of dantrolene sodium. Arch Phys Med Rehabil 1974; 55: 373-383.
79. Chyatte SB, Birdsong JH, Bergman BA: The effects of dantrolene sodium on spasticity and motor performance in hemiplegia. South Med J 1971; 64 (2): 180-185.
80. Weiser R, Terenty T, Hudgson P, et al: Dantrolene sodium in the treatment of spasticity in chronic spinal cord disease. Practitioner 1978; 221:123-127.
81. Gelenberg AJ, Poskanzer DC: The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology 1973; 23:1313-1315.
82. Tolosa ES, Soll RW, Loewenson RB: Treatment of spasticity in multiple sclerosis with dantrolene. JAMA 1975; 233(10):1046.
83. Haslam RHA, Walcher JR, Lietman PS, et al: Dantrolene sodium in children with spasticity. Arch Phys Med Rehabil 1974; 35:384-388.
84. Schmidt RT, Lee RH, Spehlman R: Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psychiatry 1976; 39:350-356.
85. Nogen AG: Medical treatment for spasticity in children with cerebral palsy. Child's Brain 1976; 2:304-308.
86. Glass A, Hannah A: A comparison of dantrolene sodium and diazepam in the treatment of spasticity. Paraplegia 974; 12:170-174.
87. Mandac BR, Hurvitz EA, Nelson VS: Hyperthermia associated with baclofen withdrawal and increased spasticity. Arch Phys Med Rehabil 1993; 74:96-97.
88. Utili R, Boitnott JK, Zimmerman HJ: Dantrolene associated hepatic injury: incidence and character. Gastroenterology 1977; 72:610.
89. 2 and in the chronic hyperalgia in rats with streptozotocin-induced diabetes. Pain 1995; 63:33-37.
90. Bonicalzi V, Canavero S: Lamotrigine effects on chronic pain: an open-label pilot study (Abstract). Proceedings of the 8th World Congress of Pain, 1996; 173.
91. Bensimon G, Lacomblez L, Meininger V, et al: A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330(9):585-591.
92. Stein R, Nordal HJ, Oftedal SI, Slettebo M: The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spasticity drug tizanidine compared with baclofen. Acta Neurol Scand 1987; 75:190-194.
93. Nance PW, Shears AH, Nance DM: Reflex changes induced by clonidine in spinal cord injured patients. Paraplegia 1989; 27:296-301.
94. Mai J: Depression of spasticity by alpha-adrenergic blockade. Acta Neurol Scand 1978; 57:65-76.
95. Sayers AC, Burki HR, Eichenberger E: The pharmacology of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadazole (DS 103 282), a novel myotonolytic agent. Arzneimittel-Forsch 1980; 30:793-803.
96. Coward DM, Davies J, Herrling P, Rudeberg C: Pharmacological Properties of Tizanidine (DS103-282). New York, FK Schattattauer Verlag, 1984, pp 61-71.
97. Davies J: Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadazole (DS 103 282). Br J Pharmacol 1982; 76:473-481.
98. Newman PM, Nogues M, Newman PK, et al: Tizanidine in the treatment of spasticity. Eur J Clin Pharmacol 1982; 23:31-35.
99. Kameyama T, Nabeshima T, Sugimoto A, Matsuno K, Yamada S: Antinociceptive action of tizanidine in mice and rats. Naunyn-Schmiedeberg's Arch Pharmacol 1985; 330:93-96.
100. Davies J, Johnston SE: Selective antinociceptive effects of tizanidine (DS 103-282), a centrally acting muscle relaxant, on dorsal horn neurones in the feline spinal cord. Br J Pharmacol 1984; 82:409-421.
101. Davies J, Johnston SE, Hill DR, Quinlan JE: Tizanidine (DS 103-282), a centrally acting muscle relaxant, selectively depresses excitation of feline dorsal horn neurones to noxious peripheral stimuli by an action at alpha adrenoceptors. Neurosci Lett 1984; 48:197-202.
102. Delwaide PJ: Electrophysiological testing of spastic patients: its potential usefulness and limitations, in Delwaide PJ, Young RR (eds): Clinical Neurophysiology in Spasticity. Amsterdam, Elsevier, 1985, pp 185-203.
103. Lapierre Y, Bouchard S, Tansey C, et al. Treatment of spasticity with tizanidine in multiple sclerosis. Can J Neurol Sci 1987; 14:513-517.
104. The United Kingdom Tizanidine Study Group: A double-blind placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994; 44(Suppl 9): 70-79.
105. Bes A, Eyssette M, Pierrot-Deseilligny E, Rohmer T, Warter JM: A multi-centre, double-blind trial of tizanidine as antispastic agent, in spasticity associated with hemiplegia. Curr Med Res Opinion 1988; 10(10):709-718.
106. Knutsson E, Martensson A, Gransberg L: Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis. J Neurol Sci 1982; 53:187-204.
107. Bass B, Weinshenker B, Rice GPA, et al: Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1988; 15(1):15-19.
108. Hutchinson DR: Modified release tizanidine: a review. J Intern Med Res 1989; 17:565-573.
109. Smith C, Birnbaum G, et al: Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology 1994; 44 (Suppl 9):34-44.
110. Nance PW, Bugaresti J, Shellenberger K, Sheremata W, Martinez-Arizala A, and the North American Tizanidine Study Group: Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. Neurology 1994; 44(suppl 9):44-53.
111. Corston RN, Johnson F, Godwin-Austen RB: The assessment of drug treatment of spastic gait. J Neurol Neurosurg Psychiatry 1981; 44:1035-1039.
112. Hassan N, McLellan DL: Double-blind comparison of single doses of DS103-282, baclofen, and placebo for suppression of spasticity. J Neurol Neurosurg Psychiatry 1980; 43:1132-1136.
113. Heazlwood V, Symoniw P, Maruff P, et al: Tizanidine-initial pharmacokinetic studies in patients with spasticity. Eur J Clin Pharmacol 1983; 25:65-67.
114. Smolenski C, Muff S, Smolenski-Kautz S: A double-blind comparative trial of a new muscle-relaxant, tizanidine (DS102-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin 1981; 7(6):374-383.
115. Hoogstraten MC, van der Ploeg RJO, Van der Burg W, et al: Tizanidine versus baclofen in the treatment of multiple sclerosis patients. Acta Neurol Scand 1988; 77:224-230.
116. Stein R, Nordal HJ, Oftedal SI, Slettebo M: The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spasticity drug tizanidine compared with baclofen. Acta Neurol Scand 1987; 75:190-194.
117. Eyssette M, Rohmer F, Serratrice G, et al: Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin 1988; 10(10):699-708.
118. Emre M: Review of clinical trials with Sirdalud® in spasticity, in Emre M, Benecke R (eds): Spasticity. London, Parthenon Publishing, 1989.
119. Kobinger W, Walland A: Investigations into the mechanisms of the hypotensive effect of 2,(2,6-dichlorophenylamino)2-imidazoline HCl. Eur J Pharmacol 1967; 2:155-162.
120. Starke K, Borowski E, Endo T: Preferential blockade of presynaptic alpha-adrenoreceptors by yohimbine. Eur J Pharmacol 1975; 34:385-388.
121. Unnerstall JR, Kopajtic TA, et al: Distribution of alpha-2 agonist binding sites in the rat and human central nervous system. Brain Res Rev 1984; 7:69-101.
122. Schomburg ED, Steffens H: The effect of DOPA and clonidine on reflex pathways from group II afferents to alpha-motoneurons in the cat. Exp Brain Res 1988; 71:442-446.
123. Donovan WH, Carter RE, Rossi CD, Wilkerson MA: Clonidine effect on spasticity: a clinical trial. Arch Phys Med Rehabil 1988; 69:193-194.
124. Nance PW, Shears AH, Nance DM: Clonidine in spinal cord injury. Can Med Assoc J 1985; 133: 41-42.
125. Weingarden SI, Belen JG: Clonidine transdermal system for treatment of spasticity in spinal cord injury. Arch Phys Med Rehabil 1992; 73:876-877.
126. Yablon SA, Sipski ME: Effect of transdermal clonidine on spinal spasticity: a case series. Am J Phys Med Rehabil 1993; 72:154-157.
127. White C de B, Richens A: Thymoxamine and spasticity. Lancet 1974; i(859):686-687.
128. Yuill GM, Neary D: Thymoxamine ineffective against spasticity. Lancet 1973; ii:1504.
129. Barbeau H, Richards CL, Bedard BJ: Action of cyproheptadine in spastic paraparetic patients. J Neurol Neurosurg Psychiatry 1982; 45:923-926.
130. Wainberg M, Barbeau H: Modulatory action of cyproheptadine in spastic paraparetic patients (Abstract). Soc Neurosci 1986; 308.5:1133.
131. Nance P: A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. J Am Paraplegia Soc 1994; 17:151-157.
132. Casale R, Glynn C, Buonocore M: Reduction of spastic hypertonia in patients with spinal cord injury: a double-blind comparison of intravenous orphenadrine citrate and placebo. Arch Phys Med Rehabil 1995; 76:660-665.
133. O'Shaughenessy WB: On the preparation of the Indian hemp or ganja. Trans Med Phys Soc Bombay 1842; 8:421-461.
134. Reynolds JR: On the therapeutic uses and toxic effects of Cannabis indica. Lancet 1890; 1:637-638.
135. Dunn M, Davis R: The perceived effects of marijuana on spinal cord injured males. Paraplegia 1974; 12:175.
136. Petro DJ, Ellenberger C: Treatment of human spasticity with delta-9-tetrahydrocannabinol. J Clin Pharmacol 1981; 21:413S-416S.
137. Clifford DB: Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983; 13:669-671.
138. Stern P, Bokonjic R: Glycine therapy in 7 cases of spasticity. Pharmacology 1974; 12:117-119.
139. Barbeau A, Roy M, Chouza C: Pilot study of threonine supplementation in human spasticity. Can J Neurol Sci 1982; 9(2):141-145.
140. Ashby P, Burke D, Rao S, et al: Assessment of cyclobenzaprine in the treatment of spasticity. J Neurol Neurosurg Psychiatry 1972; 35:599-605.
141. McNamara JO: Drugs Effective in the Therapy of the Epilepsies, in Hardman JG, Limbird LE, Molinoff PB, Ruddon RW (eds): Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edition. New York, McGraw Hill, 1996, pp 461-486.
142. Cohan SL, Raines A, Panagakos J, et al: Phenytoin and chlorpromazine in the treatment of spasticity. Arch Neurol 1980; 37:360-364.
143. Matthews WB, Rushworth G, Wakefield GS: Dimethothiazine in spasticity. Acta Neurol Scand 1972; 48:635-644.
144. Addis-Jones CD, Addlestone G, Allebone P, et al: A phenothiazine in spasticity. Practitioner 1973; 210:429-431.
145. Burke D, Hammond C, Skuse N, et al: A phenothiazine derivative in the treatment of spasticity. J Neurol Neurosurg Psychiatry 1975; 38:469-474.
146. Penn RD: Intrathecal baclofen for severe spasticity. Ann NY Acad Sci 1988; 531:157-166.
147. Penn RD, Savoy SM, Corcos D, et al: Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320:1517-1521.
148. Ochs G, Struppler A, Meyerson BA, et al: Intrathecal baclofen for long-term treatment of spasticity: a multicentre study. J Neurol Neurosurg Psychiatry 1989; 52:933-939.
149. Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J: Continuous lntrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993; 270:2475-2477.
150. Bucholz RD. Management of intractable spasticity with intrathecal baclofen, in Katz RT (ed): "Spasticity" State of the Art Reviews in Physical Medicine and Rehabilitation. Volume 8, Number 3 Philadelphia, Hanley & Belfus, 1994.
151. Jones RF, Anthony M, Torda TA, et al: Epidural baclofen for intractable spasticity. Lancet 1988; i (8584):527.
152. Dralle D, Müller H, Zierski J, Klug N: Intrathecal baclofen for spasticity. Lancet 1985; (8462): 1003.
153. Intrathecal baclofen for spasticity. Med Lett Drugs Ther 1994; 36 (917):21-22.
154. Nance PW, Schryvers OI, Schmidt BJ, Dubo HI, Loveridge B, Fewer HD: Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effects on hospital admissions. Can J Neurol Sci 1995; 22:122-129.
155. Becker W, Letts L: Intrathecal baclofen for adults with spinal spasticity. Can J Neurol Sci 1995; 22: 122-129.
156. Hankey GJ, Stewart-Wynne EG, Perlmann D: Intrathecal baclofen for severe spasticity. Med J Aust 1986; 145:465-466.
157. Müller H, Zierski J, Dralle D, Borner U, Hoffman O: The Effect of Intrathecal Baclofen in Spasticity, in Müller H, Zierski J, Penn RE (eds): Local Spinal Therapy of Spasticity. Berlin, Springer-Verlag, 1988: pp 155-214.
158. Siegfried J, Rea GL: Intrathecal application of drugs for muscle hypertoma. Scand J Rehab Med 1988; 17 (Suppl): 145-148.
159. Erickson DL, Lo J, Michaelson M: Control of intractable spasticity with intrathecal morphine sulfate. Neurosurgery 1989; 24:236-238.
160. Erickson DL, Blacklock JB, Michaelson M, et al: Control of spasticity by implantable continuous flow morphine pump. Neurosurgery 1985; 16(2):215-217.
161. Mather LE, Cousins MJ: Pharmacology of opioids: part 2. Clinical aspects. Med J Aust 1986; 44:475-481.
162. Glass PSA: Respiratory depression following only 0.4 mg of intrathecal morphine. Anesthesiology 1984; 60:256-257.
163. Müller H, Zierski J, Dralle D, Borner U, Hoffman O: Clinical Experience with Spinal Morphine, Midazolam and Tizanidine in Spasticity, in Müller H, Zierski J, Penn RE (eds): Local Spinal Therapy of Spasticity. Berlin, Springer-Verlag, 1988, pp 143-150.